Skip to main content

Advertisement

SpringerLink
Log in

Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The purpose of this study is to provide more definite evidence regarding the role of dose modification of chemotherapy in obese women with breast cancer by systematically reviewing current literature regarding chemotherapy-induced toxicity rates in obese and non-obese women with early-stage breast cancer. A systematic search of Pubmed and EMBASE was conducted to identify original studies investigating chemotherapy-induced toxicity in obese women receiving adjuvant chemotherapy treatment for breast cancer. Ten studies were identified. We noted low rates of adjustment for confounders such as prophylactic hematopoietic growth factor use and empirical dose reductions. Seven studies found reduced toxicity in obese compared to non-obese women. Of four studies, where dose capping was precluded or statistically adjusted for, three found reduced toxicity in obese women. These outcomes include less febrile neutropenia (body mass index (BMI) >23.6; odds ratio (OR) 4.4; 95 % confidence interval (CI) 1.65–12.01), fewer hospital admissions (BMI >35; OR 0.61, 95 % CI 0.38–0.97), and fewer neutropenic events (BMI >25; OR 0.49; 95 % CI 0.37–0.66). Only a single study reported higher rates of toxicity in obese women, but this study had significant methodological issues. As a conclusion, we observed that obese patients tolerate chemotherapy better than lean patients. However, this may be confounded by poorly specified dose capping practices and the use of hematopoietic growth factors. Further research should focus on improved documentation of body size, of dose, and of use of growth factors, and analysis of how these affect recurrence rates, toxicity, and survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578

    Article  PubMed  Google Scholar 

  2. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635

    Article  PubMed  Google Scholar 

  3. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87

    Article  PubMed  CAS  Google Scholar 

  4. Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41(3–4):458–463

    Article  PubMed  CAS  Google Scholar 

  5. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54(2):131–139

    Article  PubMed  CAS  Google Scholar 

  6. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13(11):3264–3268

    Article  PubMed  CAS  Google Scholar 

  7. Sparreboom A, Wolff AC, Mathijssen RHJ, Chatelut E, Rowinsky EK, Verweij J, Baker SD (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25(30):4707–4713

    Article  PubMed  CAS  Google Scholar 

  8. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA (2009) Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). Cancer Treat Rev 35(1):69–78

    Article  PubMed  CAS  Google Scholar 

  9. Thompson LA, Lawson AP, Sutphin SD, Steinke D, Adams VR (2010) Description of current practices of empiric chemotherapy dose adjustment in obese adult patients. J Oncol Pract 6(3):141–145

    Article  PubMed  Google Scholar 

  10. Field KM, Kosmider S, Jefford M, Michael M, Jennens R, Green M, Gibbs P (2008) Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 4(3):108–113

    Article  PubMed  Google Scholar 

  11. Greenman CG, Jagielski CH, Griggs JJ (2008) Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer 112(10):2159–2165

    Article  PubMed  CAS  Google Scholar 

  12. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215–231

    Article  PubMed  CAS  Google Scholar 

  13. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15

    Article  PubMed  CAS  Google Scholar 

  14. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL et al. (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 30(13):1553–61

    Google Scholar 

  15. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia-risks, consequences, and new directions for its management. Cancer 100(2):228–237

    Article  PubMed  Google Scholar 

  16. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR et al (1994) Dose and dose intensity of adjuvant chemotehrapy for stage-II, node-positive breast-carcinoma. N Engl J Med 330(18):1253–1259

    Article  PubMed  CAS  Google Scholar 

  17. Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A, Szucs TD, Leonard R (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU prospective observational European neutropenia study. Support Care Cancer 19(4):483–490

    Article  PubMed  Google Scholar 

  18. Chan A, Chen C, Chiang J, Tan SH, Ng R (2011) Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer. 20(7):1525–32

    Google Scholar 

  19. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02–98 trial. Breast Cancer Res Treat 119(1):145–153

    Article  PubMed  Google Scholar 

  20. Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S, Simoncini E et al (2008) Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 16(1):67–74

    Article  PubMed  Google Scholar 

  21. Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165(11):1267–1273

    Article  PubMed  Google Scholar 

  22. Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Gluck S (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47(17):2537–2545

    Google Scholar 

  23. Jenkins P, Elyan S, Freeman S (2007) Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 43(3):544–548

    Article  PubMed  CAS  Google Scholar 

  24. Poikonen P, Blomqvist C, Joensuu H (2001) Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 40(1):67–71

    Article  PubMed  CAS  Google Scholar 

  25. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia Group B study 8541. J Clin Oncol 14(11):3000–3008

    PubMed  CAS  Google Scholar 

  26. Schwenkglenks M, Jackisch C, Constenla M, Kerger JN, Paridaens R, Auerbach L, Bosly A, Pettengell R, Szucs TD, Leonard R (2006) Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 14(9):901–909

    Article  PubMed  Google Scholar 

  27. NCI (2010) Common Terminology Criteria for Adverse Events Version 4.03. In. Edited by Institute NC: National Cancer Institute

  28. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301–305

    Article  PubMed  CAS  Google Scholar 

  29. Brosteanu O, Hasenclever D, Loeffler M, Diehl V (2004) Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease. Ann Hematol 83(3):176–182

    Article  PubMed  CAS  Google Scholar 

  30. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, Fuchs CS (2003) Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98(3):484–495

    Article  PubMed  Google Scholar 

  31. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, Wolmark N (2006) Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98(22):1647–1654

    Article  PubMed  Google Scholar 

  32. Lopes-Serrao MD, Ussery SM, Hall RG 2nd, Shah SR (2011) Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract 7(1):13–17

    Article  PubMed  Google Scholar 

  33. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW (2011) The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 117(5):948–956

    Article  PubMed  Google Scholar 

  34. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O’Connell MJ, Mayer RJ, Cummings B, Willett C et al (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22(4):648–657

    Article  PubMed  Google Scholar 

  35. Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European neutropenia study. Br J Haematol 144(5):677–685

    Article  PubMed  Google Scholar 

  36. Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA (2008) Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 109(3):353–358

    Article  PubMed  CAS  Google Scholar 

  37. Modesitt SC, Tian C, Kryscio R, Thigpen JT, Randall ME, Gallion HH, Fleming GF (2007) Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol 105(1):59–65

    Article  PubMed  CAS  Google Scholar 

  38. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25(2):139–142

    Article  PubMed  CAS  Google Scholar 

  39. Overweight and obesity in adults (2008). In. Canberra: Australian Bureau of Stastics

  40. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20(3):219–222

    Article  PubMed  CAS  Google Scholar 

  41. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6(8):1321–1327

    PubMed  CAS  Google Scholar 

  42. Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR (2007) Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomark Prev 16(5):1026–1031

    Article  CAS  Google Scholar 

  43. Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ et al (2006) Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17(1):85–92

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

No conflicts of interest declared.

Author information

Authors and Affiliations

  1. University of Queensland Princess Alexandra-Southside Clinical School, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD, 4012, Australia

    James Carroll, Melinda Protani, Euan Walpole & Jennifer H. Martin

  2. School of Population Health, University of Queensland, Herston Road, Herston, QLD, 4006, Australia

    Melinda Protani

  3. Division of Cancer Care, Princess Alexandra Hospital, Woolloongabba, QLD, Australia

    Euan Walpole

  4. Division of Internal Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia

    Jennifer H. Martin

  5. PO Box 106, Nundah, QLD, 4012, Australia

    James Carroll

Authors
  1. James Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melinda Protani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Euan Walpole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer H. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Carroll.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carroll, J., Protani, M., Walpole, E. et al. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Res Treat 136, 323–330 (2012). https://doi.org/10.1007/s10549-012-2213-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2213-3

Keywords

Search

Navigation